TL;DR
This study integrated network pharmacology, transcriptomics, and proteomics to elucidate the protective mechanisms of FF against ALI and revealed that 11 core components mediated anti-ALI effects by modulating 347 targets across 25 signaling pathways.
Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a progressive condition predisposing to cirrhosis and hepatocellular carcinoma, with prevalence rising globally. Yet effective therapies remain limited. Wuzhi Dripping Pills (WZDP), derived from Schisandra sphenanthera, possess hepatoprotec...
BACKGROUND Current pharmacotherapies for chronic kidney disease (CKD) are limited by adverse effects and a "one-target-one-drug" paradigm. Necroptosis is a key driver of renal deterioration, yet its regulatory network remains poorly defined. Modified Da-Huang-Fu-Zi Decoction (DHFZ) has shown clinical efficacy, although...
Results suggest SYH mitigates ALI by inhibiting the pro-inflammatory TLR4/MYD88/NF-κB pathway and activating the antioxidant Keap-1/Nrf2/HO-1/NQO1 pathway.
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive immunometabolic liver disorder involving lipid dysregulation, inflammation, fibrosis, and extrahepatic immune–neural responses, yet therapies capable of modulating these interconnected processes remain limited. Berberine (BBR), an isoquinoline alk...
SDFE can ameliorate LPS-induced ALI by inhibiting leukocyte adhesion and reducing oxidative stress, and Kyoto Encyclopedia of Genes and Genomes pathway analysis indicated that leukocyte adhesion and oxidative stress are two key signaling pathways involved in the therapeutic effects of SDFE against ALI.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
